UCLA researchers have found that a Chinese herbal regimen known as TSY-1 (Tianshengyuan-1) increased telomerase activity in normal bloodstream cells but decreased it in cancer cells. Telomerase is an enzyme responsible for the production of telomeres, which perform an important role in the regulation of normal cell department. These results indicate that telomerase-based treatments may enjoy an important role in treating both blood cell deficiency plus cancer.
More than 80 % of cancers have increased telomerase activity, and other health conditions are also associated with decreased or abnormal telomerase function. The opportunity to increase or decrease telomerase activity has important effects for treating cancers in which insufficient numbers of blood tissue are produced. When a person’s bone marrow is unable to maintain the need for healthy blood cells, bone marrow failure is certainly triggered. Bone marrow failure affects about seven within 100, 000 people annually.
TSY-1 continues to be used in China for many years to treat aplastic anemia, a condition where the body stops producing enough new blood cells plus myelodysplastic syndrome or preleukemia; both are associated with telomerase abnormality.
The five-year study, led simply by UCLA Jonsson Comprehensive Cancer Center member Dr . Jianyu Rao, measured the ability of TSY-1 to affect telomerase activity in cancer cells lines, including one generally known as HL-60, as well as normal peripheral blood mononuclear and hematopoietic stem cells. Rao’s team used various approaches, which includes assays of telomerase activity, measurement of cell development, and gene expression profiling of TSY-1 treated tissues, to determine how it acts. The results showed that the target associated with TSY-1 activity is the TERT gene. TERT is the main regulatory component of telomerase activity.
The results provide the foundation and support for further clinical studies to show the clinical benefit of this treatment for cancer and bloodstream cell deficiencies.
The study is published on the internet in the journal OncoTarget .
Materials provided by University associated with California, Los Angeles (UCLA), Health Sciences . Original authored by Reggie Kumar. Note: Content may be modified for style and length.